银丹心脑通联合钙通道阻断剂治疗高血压患者的疗效及安全性分析

Efficacy and safety of yindanxinnaotong combined with calcium channel blocker in the treatment of hypertension

目的分析在为高血压患者实施治疗的过程中联合运用银丹心脑通与钙通道阻断剂的临床疗效与安全性。方法此研究随机在2020年1月-2022年10月之间于天津市和平区南营门街社区卫生服务中心接受高血压治疗的患者中选取90例作为实验对象,采用随机数字表法实现患者的分组,其中45例患者的治疗方法为钙通道阻断剂,将其作为参照组,另外45例患者的治疗方法为银丹心脑通+钙通道阻断剂,将其作为研究组。结果治疗前两组患者中医证候积分、血压水平、心率、血脂水平和不良反应发生率均无显著差异,P>0.05;研究组患者治疗有效率相对较高,且治疗后上述指标显著差别于参照组患者,存在显著统计学差异,P<0.05。结论在实施高血压患者治疗的过程中银丹心脑通+钙通道阻断剂是一种理想的用药方案,具有较为显著的临床疗效以及安全性。

Objective To analyze the clinical efficacy and safety of yindanxinnaotong combined with calcium channel blocker in the treatment of hypertension.Methods 90 patients with hypertension were selected randomly from our hospital from January 2020 to October 2022.The patients were grouped by random number table,forty-five patients were treated with calcium channel blocker as the control group,and the other 45 patients were treated with yindanxinnaotong and calcium channel blocker as the research group.Results Before treatment,there were no significant differences in TCM symptom scores,blood pressure level,heart rate,blood lipid level and adverse reaction rate between the two groups,P>0.05.The effective rate in the study group was relatively higher than that in the control group,after treatment,the above indexes were significantly different from those of the control group,there was a significant statistical difference(P<0.05).Conclusion Yindanxinnaotong+calcium channel blocker is an ideal medication for treating hypertension,and has significant clinical efficacy and safety.